Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 2/2005

01-06-2005 | ORIGINAL ARTICLE

Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism

Authors: Yuko Oyama, Junichiro James Kazama, Kentaro Omori, Noboru Higuchi, Shigemi Kameda, Suguru Yamamoto, Yumi Ito, Hiroki Maruyama, Ichiei Narita, Fumitake Gejyo

Published in: Clinical and Experimental Nephrology | Issue 2/2005

Login to get access
Metadata
Title
Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism
Authors
Yuko Oyama
Junichiro James Kazama
Kentaro Omori
Noboru Higuchi
Shigemi Kameda
Suguru Yamamoto
Yumi Ito
Hiroki Maruyama
Ichiei Narita
Fumitake Gejyo
Publication date
01-06-2005
Publisher
Springer-Verlag
Published in
Clinical and Experimental Nephrology / Issue 2/2005
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-005-0342-2

Other articles of this Issue 2/2005

Clinical and Experimental Nephrology 2/2005 Go to the issue

ORIGINAL ARTICLE

Prevalence of human polyoma virus (BK virus and JC virus) infection in patients with chronic renal disease

ORIGINAL ARTICLE

Effects of low dialysate calcium concentration on health-related quality of life in hemodialysis patients

CASE REPORT

Tuberous sclerosis, associated with renal cell carcinoma and angiomyolipoma, in a patient who developed endstage renal failure after nephrectomy

ORIGINAL ARTICLE

Post-transplant diabetes mellitus: risk factors, frequency of transplant rejections, and long-term prognosis

REVIEW ARTICLE

Renal tubular transport and the genetic basis of hypertensive disease

ORIGINAL ARTICLE

Glutathione peroxidase activity in patients with renal disorders
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits